PCAS

PCAS is a French fine and specialty chemicals company focused on process development and manufacturing of complex molecules for life sciences and specialty chemicals customers. In healthcare, the company has operated primarily as a contract development and manufacturing organization, with capabilities spanning active pharmaceutical ingredients, advanced intermediates, and certain drug-delivery and excipient products. PCAS has historically served pharmaceutical and biotech customers through GMP manufacturing and process R&D rather than through a proprietary clinical drug pipeline. The company became part of Seqens and was taken private following Seqens' simplified tender offer and squeeze-out in 2023. PCAS remains an operating business within the Seqens group.